Manufacturing process
Defined batch conditions, repeatability and measured resource use. These findings do not establish a skin benefit.
RESEARCH & VALIDATION
The important question is not just whether a result exists. It is what was tested, how it was measured and what the result can establish.
CURRENT DEVELOPMENT BASIS
The supplied company materials describe internal lab-scale formulation and process testing. This website does not present that work as completed clinical validation or repeatable commercial manufacture.
Full supporting protocols and raw data are not published here. Request the current status and the approved material available for review.
DISTINCT EVIDENCE TYPES
Defined batch conditions, repeatability and measured resource use. These findings do not establish a skin benefit.
Active integrity, rheology, stability, microbiology and packaging compatibility, as appropriate to the formulation.
Relevant assessment of the exact formula, intended use and advertised outcome.
Published work using other formulations or materials, attributed as context rather than OPP proof.
DEVELOPMENT MILESTONES
Work reported to date
Integrated formulation and process work described in company materials; not an independently verified performance claim.
Further validation
Define the test article, method, comparator, endpoints and limitations before publishing results.
Scale-up gate
Establish documented batch scale, acceptance criteria and consistency across relevant runs.
Product-specific gate
Complete the relevant safety, stability, microbiology, compatibility and claim-support requirements.
Future gate
Establish repeatable production and release arrangements before individual products enter supply.
Parallel workstream
Keep patent status, confidentiality and technical disclosure under appropriate review.
R&D PROGRAMME
GlowSense R&D activities are registered under the Australian Government R&D Tax Incentive programme, as reported by the company. Status below is company-reported and is not independent verification.
Australian provisional applications relating to OPP have been filed, as reported by the company. A provisional filing does not grant patent rights.
Preliminary bench work on spicule sizing, purity and morphology, reported internally.
Batch manufacturing records being developed for trial formulations, in line with GMP documentation practice.
Formulation dossiers, stability testing protocols and CoA frameworks in development for selected formulations.
Quantitative analytical testing of active stability before and after OPP co-formulation.
Extending the OPP approach beyond gel and serum formats, assessed for each new format.
International filing under the PCT route, as part of the intellectual-property workstream.
Planned work is not a completed result, and target dates are not commitments. Contact GlowSense for current status.
BACKGROUND RESEARCH
A 2017 study investigated Haliclona spicules with model dextrans using laboratory and animal models. It did not test GlowSense OPP or a PERVIA serum.
It can inform research questions, but it does not substantiate a PERVIA-specific PDRN delivery, human safety or clinical benefit claim.
PUBLISHED LITERATURE
Published work on spicule-based delivery that informs our research questions. None of these studies tested GlowSense OPP or a PERVIA product.
Molecular Pharmaceutics · 2017
Zhang et al. Laboratory and animal models using model dextrans. Did not test GlowSense OPP or a PERVIA serum.
Pharmaceutics (MDPI) · 2021
Compares several marine sponge spicule species using a model peptide in laboratory settings. Background context only.
PMC · 2025
Single-arm study of a different spicule-based system and ingredient. It does not establish OPP or PERVIA outcomes.
OUR PUBLICATION STANDARD
We do not apply a published penetration multiple to an untested OPP product, present a planned study as complete or imply that a laboratory result establishes a clinical outcome.
Numerical retention and resource-saving claims remain outside this public copy until their methods, scope and evidence have been reviewed.
Technology, evidence and business enquiries.